Search Results
ACIS Trial of Apalutamide and Abiraterone in Chemotherapy-Naïve mCRPC
Results from ACIS Trial of Apalutamide + Abiraterone/Prednisone in Patients with Chemo-Naive mCRPC
A Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in mCRPC
Apalutamide in combination with abiraterone acetate, docetaxel and prednisone for mCRPC
Dr. Saad on the Clinical Impact of Apalutamide in nmCRPC
Tanya Dorff, MD, explains the design and outcomes of the ACIS clinical trial
Eleni Efstathiou, MD, PhD, offers opinion on the ACIS clinical trial
Abiraterone acetate/prednisone + apalutimide and ADT + post-op SRT may improve PFS and MFS
Elisabeth Heath, MD, FACP, explains the design and outcomes of the ACIS study from ASCO GU 2021
William K. Oh, MD, summarizes outcomes from the ACIS study as presented at ASCO GU 2021
Dr. Yu on the Association of ALP With Outcomes in Chemotherapy-Naïve Patients With mCRPC
STARTAR: AR inhibition + ADT + apalutamide + RT + docetaxel for salvage in PSA recurrent PC after RP
